Literature DB >> 35723796

ROR2 promotes epithelial-mesenchymal transition by hyperactivating ERK in melanoma.

María Victoria Castro1,2, Gastón Alexis Barbero1,2, Paula Máscolo1, María Belén Villanueva1,2, Jérémie Nsengimana3, Julia Newton-Bishop4, Edith Illescas1, María Josefina Quezada1,2, Pablo Lopez-Bergami5,6.   

Abstract

Receptor tyrosine kinase-like orphan receptor 2 (ROR2) is a protein with important functions during embryogenesis that is dysregulated in human cancer. An intriguing feature of this receptor is that it plays opposite roles in different tumor types either promoting or inhibiting tumor progression. Understanding the complex role of this receptor requires a more profound exploration of both the altered biological and molecular mechanisms. Here, we describe that ROR2 promotes Epithelial-Mesenchymal Transition (EMT) by inducing cadherin switch and the upregulation of the transcription factors ZEB1, Twist, Slug, Snail, and HIF1A, together with a mesenchymal phenotype and increased migration. We show that ROR2 activates both p38 and ERK mitogen-activated protein kinase pathways independently of Wnt5a. Further, we demonstrated that the upregulation of EMT-related proteins depends on the hyperactivation of the ERK pathway far above the typical high constitutive activity observed in melanoma. In addition, ROR2 also promoted ERK phosphorylation, EMT, invasion, and necrosis in xenotransplanted mice. ROR2 also associates with EMT in tumor samples from melanoma patients where analysis of large cohorts revealed that increased ROR2 levels are linked to EMT signatures. This important role of ROR2 translates into melanoma patient' s prognosis since elevated ROR2 levels reduced overall survival and distant metastasis-free survival of patients with lymph node metastasis. In sum, these results demonstrate that ROR2 contributes to melanoma progression by inducing EMT and necrosis and can be an attractive therapeutic target for melanoma.
© 2022. The International CCN Society.

Entities:  

Keywords:  EMT; ERK; Invasion; Melanoma; Migration; ROR2; Tumor necrosis

Year:  2022        PMID: 35723796     DOI: 10.1007/s12079-022-00683-1

Source DB:  PubMed          Journal:  J Cell Commun Signal        ISSN: 1873-9601            Impact factor:   5.782


  48 in total

Review 1.  The dual role of the novel Wnt receptor tyrosine kinase, ROR2, in human carcinogenesis.

Authors:  Caroline E Ford; Sean Si Qian Ma; Ashfaque Quadir; Robyn L Ward
Journal:  Int J Cancer       Date:  2013-01-10       Impact factor: 7.396

2.  A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis.

Authors:  Soledad R Alonso; Lorraine Tracey; Pablo Ortiz; Beatriz Pérez-Gómez; José Palacios; Marina Pollán; Juan Linares; Salvio Serrano; Ana I Sáez-Castillo; Lydia Sánchez; Raquel Pajares; Abel Sánchez-Aguilera; Maria J Artiga; Miguel A Piris; José L Rodríguez-Peralto
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

3.  A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma.

Authors:  Julie Caramel; Eftychios Papadogeorgakis; Louise Hill; Gareth J Browne; Geoffrey Richard; Anne Wierinckx; Gerald Saldanha; Joy Osborne; Peter Hutchinson; Gina Tse; Joël Lachuer; Alain Puisieux; J Howard Pringle; Stéphane Ansieau; Eugene Tulchinsky
Journal:  Cancer Cell       Date:  2013-09-26       Impact factor: 31.743

4.  The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway.

Authors:  Sharon DeMorrow; Heather Francis; Eugenio Gaudio; Julie Venter; Antonio Franchitto; Shelley Kopriva; Paolo Onori; Romina Mancinelli; Gabriel Frampton; Monique Coufal; Brett Mitchell; Bradley Vaculin; Gianfranco Alpini
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-10-02       Impact factor: 4.052

5.  ROR1 contributes to melanoma cell growth and migration by regulating N-cadherin expression via the PI3K/Akt pathway.

Authors:  Natalia Brenda Fernández; Daniela Lorenzo; María Elisa Picco; Gastón Barbero; Leonardo Sebastián Dergan-Dylon; María Paula Marks; Hernán García-Rivello; Liliana Gimenez; Vivian Labovsky; Luca Grumolato; Pablo Lopez-Bergami
Journal:  Mol Carcinog       Date:  2015-10-28       Impact factor: 4.784

6.  Filamin A Expression Negatively Regulates Sphingosine-1-Phosphate-Induced NF-κB Activation in Melanoma Cells by Inhibition of Akt Signaling.

Authors:  Ludmila S Campos; Yamila I Rodriguez; Andreia M Leopoldino; Nitai C Hait; Pablo Lopez Bergami; Melina G Castro; Emilse S Sanchez; Michael Maceyka; Sarah Spiegel; Sergio E Alvarez
Journal:  Mol Cell Biol       Date:  2015-11-09       Impact factor: 4.272

Review 7.  Ror2 as a therapeutic target in cancer.

Authors:  Zufan Debebe; W Kimryn Rathmell
Journal:  Pharmacol Ther       Date:  2015-01-19       Impact factor: 13.400

8.  WLS-Wnt signaling promotes neuroendocrine prostate cancer.

Authors:  Tyler Bland; Jing Wang; Lijuan Yin; Tianjie Pu; Jingjing Li; Jin Gao; Tzu-Ping Lin; Allen C Gao; Boyang Jason Wu
Journal:  iScience       Date:  2021-01-01

9.  ROR2 has a protective role in melanoma by inhibiting Akt activity, cell-cycle progression, and proliferation.

Authors:  María Victoria Castro; Gastón Alexis Barbero; María Belén Villanueva; Luca Grumolato; Jérémie Nsengimana; Julia Newton-Bishop; Edith Illescas; María Josefina Quezada; Pablo Lopez-Bergami
Journal:  J Biomed Sci       Date:  2021-11-13       Impact factor: 8.410

10.  ROR2 increases the chemoresistance of melanoma by regulating p53 and Bcl2-family proteins via ERK hyperactivation.

Authors:  María Victoria Castro; Gastón Alexis Barbero; Paula Máscolo; Rocío Ramos; María Josefina Quezada; Pablo Lopez-Bergami
Journal:  Cell Mol Biol Lett       Date:  2022-03-08       Impact factor: 5.787

View more
  1 in total

1.  ROR2, a driver of "phenotype switching" in melanoma?

Authors:  Pablo Lopez-Bergami
Journal:  Cancer Cell Int       Date:  2022-09-20       Impact factor: 6.429

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.